Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual MeetingPRNewsWire • 06/07/22
Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep MedicinePRNewsWire • 06/01/22
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA MeetingsPRNewsWire • 05/12/22
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome TherapeuticsPRNewsWire • 05/09/22
Jazz Pharmaceuticals' (JAZZ) CEO Bruce Cozadd on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Jazz Pharmaceuticals (JAZZ) Lags Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/04/22
Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial GuidancePRNewsWire • 05/04/22
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor AgonistPRNewsWire • 05/04/22
Jazz Pharmaceuticals to Participate in the BofA Securities 2022 Global Healthcare ConferencePRNewsWire • 05/03/22
The Best Marijuana Stocks In 2022 And The Different Cannabis Sectors To Watch Right NowMarijuanaStocks • 05/01/22
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q1 Earnings Expected to DeclineZacks Investment Research • 04/27/22
Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022PRNewsWire • 04/20/22